This listing of claims will replace all prior versions of claims in the application:

Listing of Claims: Please amend the claims as follows:

We claim:

Claim 1. (Previously Presented) A crystal of an anti-epidermal growth factor receptor (anti-EGFR) antibody which forms a biologically active antibody protein when dissolved or suspended in an aqueous medium, said crystal being obtained by a process comprising

precipitating an aqueous solution or suspension of said anti-EGFR antibody by means of a precipitation reagent,

wherein said anti-EGFR antibody is a chimeric monoclonal antibody c225 (cetuximab).

Claim 2. (Previously Presented) The crystal according to Claim 1, wherein the precipitation reagent comprises a salt, a polymer, an organic solvent, or a combination thereof.

Claim 3. (Previously Presented) The crystal according to Claim 2, wherein the precipitation reagent comprises ammonium sulfate, sodium acetate, sodium citrate, potassium phosphate, PEG and/or ethanol.

Claim 4. (Canceled)

Claim 5. (Canceled)

Claim 6. (Canceled)

Claim 7. (Canceled)

Claim 8. (Cancelled)

Claim 9. (Previously Presented) A process for the preparation of a crystal of an anti-EGFR antibody which forms a biologically active antibody protein when dissolved or suspended in an aqueous medium, said process comprising

precipitating an aqueous solution or suspension of said anti-EGFR antibody by means of a precipitation reagent, and

separating the precipitation product,

wherein said anti-EGFR antibody is monoclonal antibody c225 (cetuximab).

Claim 10. (Previously Presented) A process according to Claim 9, wherein the precipitation reagent comprises ammonium sulfate, PEG and/or ethanol.

Claim 11. (Previously Presented) A process according to Claim 9, which is carried out in batch format.

Claim 12. (Previously Presented) A storage-stable medicament which comprises a crystal of claim 1 together with a stabilizing agent.

Claim 13. (Previously Presented) A pharmaceutical preparation which comprises a pharmaceutically acceptable carrier and the crystal according to Claim 1, wherein the anti-EGFR antibody concentration is 50 – 150 mg/ml and said crystal is in crystalline, soluble, or suspended form.

Claim 14. (Cancelled)

Claim 15. (Cancelled)

Claim 16. (Cancelled)

Claim 17. (Withdrawn) A method for the treatment and/or prophylaxis of a tumor or a tumor metastasis in a subject in need thereof, comprising administering to said subject a crystal of claim 1.

Claim 18. (Withdrawn) A method according to Claim 17, wherein the tumor is brain tumor, tumor of the urogenital tract, tumor of the lymphatic system, stomach tumor, laryngeal tumor, monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinoma, pancreatic cancer, glioblastoma or breast carcinoma.

Claim 19. (Cancelled)

Claim 20. (Cancelled)

Claim 21. (Cancelled)

Claim 22. (Previously Presented) The crystal according to Claim 1, which has a size of 50–200 µm.

Claim 23. (New) The crystal according to claim 3, wherein the precipitation reagent comprises saturated ammonium sulfate solution in 10 mM phosphate, pH 8.0.

Claim 24. (New) The crystal according to claim 3, wherein the precipitation reagent comprises 50% (v/v) of ethanol in 10 mM citrate, pH 5.5.